Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution

Figure 3

EZH2 expression by qRT-PCR in pediatric patients with MDS. (a) EZH2 expression levels: low, intermediate, high and donors. (b) Donors vs low expression patients. (c) Donors vs intermediate expression patients. (d) Donors vs high expression patients.

(a)

(b)

(c)

(d)